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ABSTRACT
Aim of the study was to establish the effect of the time interval between the initial optimal cytoreductive 
surgery and the initiation of adjuvant chemotherapeutic treatment (ACT) on the overall survival (OS) of 
patients with advanced ovarian adenocarcinoma.
Materials and methods. Clinical cases of 60 patients with advanced ovarian adenocarcinoma (FIGO 
IIIC-IV), with the average age of 61 years, who underwent primary cytoreductive surgery (PDS) with the 
completeness of cytoreduction (CC) — 0 score according to Shugarbaker and adjuvant chemotherapeutic 
treatment according to the standard first-line regimen were examined. Patients were categorized depending 
on the time between surgery and chemotherapeutic treatment into two groups: I — delay of chemotherapy 
for no more than one month (30 patients), II — from two to six months (30 patients). The OS data of the 
patients obtained from the national cancer registry were analyzed. 
Results. The results demonstrate an increase in OS of patients who underwent CC-0 PDS at the early 
initiation of ACT.
Conclusions. Delaying the onset of ACT is an independent predictor of the worse OS after performing 
PDS. According to the data obtained, patients should start ACT within 1 month after the surgery. However, 
the findings are proved if CC-0 is achieved during the operation.
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Introduction
According to the National Cancer Registry of Ukraine 
2017–2018, ovarian cancer ranks seventh in the struc-
ture of the incidence of malignant neoplasms and fifth 
in the structure of mortality from them among women. 
Stage III in FIGO had 43.4%, IV — 15.5% among first 
identified patients. Nearly 25% of them did not live for 
one year. This survival is associated with a predomi-
nantly asymptomatic course of the disease in the early 
stages. Therefore the process is constantly diagnosed 
in the later stages. Ovarian cancer is classified accord-
ing to its cellular origin. Most ovarian cancers come 
from superficial (epithelial) ovarian cells and are called 
epithelial tumors, although some cancers can also arise 
from ovarian stroma, from mesenchyme of embryonic 
gonads, sex stroma, etc. The development of peritoneal 
carcinomatosis is typical for the most common variant 
of ovarian cancer (epithelial) due to cellular and mo-
lecular processes which are specific to such tumors. It 
leads to rapid exfoliation of malignant cells into the 
abdominal cavity. The main methods for the special 
treatment of epithelial ovarian cancer are surgical and 
chemotherapeutic. In recent decades the paradigm 
shift in the treatment of advanced ovarian cancer has 
been observed. It is accompanied by the introduction of 
new active methods of combined treatment. According 
to their pathophysiological properties, these tumors 
respond relatively well to cytoreductive (surgical and 
chemotherapeutic) treatment. Any decrease in the total 
tumor mass has a definite effect on the overall survival 
(OS) of patients. However, the oncological results 
of special treatment directly depend on the surgical 
radicality [1] and the intensity of chemotherapeutic 
treatment [2]. The size of the residual tumor mass after 
cytoreductive surgery is an important prognostic factor 
Corresponding author: 
Mykhailo Chetverikov, Center  
of Reconstructive and Restorative Medi-
cine (University Clinic), 8 Tinista St., 
Odesa, Ukraine,  
e-mail: chetvericov@yahoo.com
2MEDICAL RESEARCH JOURNAL 2020. vol. 5
www.journals.viamedica.pl/medical_research_journal
for the OS of such patients. The concept of the cytore-
ductive intervention was proposed by Paul H. Sugar-
baker. It is based on the principle of maximum removal 
of macroscopically visible implantation metastases from 
the abdominal cavity in order to achieve the minimum 
microscopic level of the residual intraperitoneal pool 
of tumor cells. An increase in surgical radicalness in 
patients with advanced ovarian cancer is associated 
with an increase in overall and relapse-free survival. 
Although, it may lead to prolongation of postoperative 
recovery and delay the initiation of adjuvant chemother-
apy treatment (ACT). The relationship between the inter-
val from surgery and the onset of ACT with overall and 
relapse-free survival is being investigated. Nevertheless, 
the optimal interval has not yet been determined. Most 
studies allow an interval of 6–8 weeks. Until now there 
remains the issue of the order of combined treatment 
[3, 4], the volume of resection in standard surgery [5, 
6] and the total intensity of the combined treatment, i.e., 
the time interval between each of its stages. Also, the
role of hyperthermic intraperitoneal chemoperfusion in
the treatment of advanced ovarian cancer still remains
without a final assessment [7, 8].
Aim of the study was to establish the effect of the 
time interval between the initial optimal cytoreductive 
surgery and the initiation of ACT on the OS of patients 
with advanced ovarian adenocarcinoma.
Materials and methods
Clinical cases of 60 patients with advanced ovar-
ian adenocarcinoma (FIGO IIIC-IV), with the average 
age of 61 years (interval from 37 to 71 years), who 
underwent primary cytoreductive surgery (PDS) with 
the completeness of cytoreduction (CC) — 0 score ac-
cording to Shugarbaker and adjuvant chemotherapeutic 
treatment according to the standard first-line regimen 
(three-week regimen of carboplatin administration (area 
under the concentration-time curve 5–6) and paclitaxel 
175 mg/m2) were examined. Patients were categorized 
depending on the time between surgery and chemo-
therapeutic treatment into two groups: I — delay of 
chemotherapy for no more than one month (30 pa-
tients), II — from two to six months (30 patients). The OS 
data of the patients obtained from the National Cancer 
Registry of Ukraine were analyzed. The study was con-
ducted as a part of the scientific work of the Surgery 
Department No. 4 with a course of oncology at Odessa 
National Medical University. Compliance with the WMA 
Code of Ethics of the World Medical Association WMA 
Declaration of Helsinki - Ethical Principles for Medical 
Research Involving Human Subjects 2013 (protocol of 
the meeting of the bioethics commission of the Odessa 
National Medical University No. 176a of 11/14/2019) 
was determined. All study participants were informed 
and agreed to the processing of their clinical data and 
participation in the research process.
Statistical analysis of the data was carried out using 
the GNU PSPP program version 1.2.0. Kaplan-Meier 
survival curves were constructed; the Log Rank test and 
a special case of the Peto & Peto modification of the Ge-
han-Wilcoxon test were used for statistical comparison.
Results
In the analysis of the first group of patients (the time 
interval before the start of ACT to 1 month), we obtained 
a variable series of periods (in months) between the 
start of special treatment and the establishment of death 
from the underlying disease and / or its complications: 
10, 10, 12, 14, 15, 15, 16, 17, 18, 18, 19, 19, 20, 21, 22, 
25, 26, 33, 35, 39, 43, 43, 43, 51, 53, 56, 63, 85, 101, 
126. Variation indices: weighted average — 36, mode
— 43, median — 26, standard deviation — 27.513.
In the analysis of the second group of patients (the 
time interval before the start of ACT from 2 to 6 months), 
we obtained a variable series of periods (in months) 
between the start of special treatment and the establish-
ment of death from the underlying disease and / or its 
complications: 5, 5, 5, 5, 6 , 6, 12, 12, 12, 12, 14, 14, 18, 
18, 19, 19, 19, 19, 19, 19, 19, 19, 19, 19, 19, 27, 27, 35, 
35, 40, 40. Variation indices: weighted average — 18, 
mode — 19, median — 19, standard deviation — 9.76.
Survival functions and confidence intervals are 
calculated using the obtained variational series, 
a table of the lifetime is constructed (Tab. 1.1, 1.2, 2). 
Kaplan-Meier plots were constructed for a graphical in-
terpretation of the results (Fig. 1). Log Rank criterion was 
used to test the hypothesis of various survival rates in 
groups: xi-square 10.485957, p = 0.001203 (p < 0.05), 
and a special case of the Peto & Peto modification 
of the Gehan-Wilcoxon test: xi-square 8.493086, 
p = 0.003565 (p < 0.05)
Discussion of the results
The results demonstrate an increase in OS of patients 
who underwent CC-0 PDS with early ACT initiation. Intra-
operative seeding by tumor cells is one of the reasons 
for the growth of residual micrometastases in the interval 
between surgical resection of the tumor and chemother-
apeutic treatment. Such micrometastases are most sen-
sitive to chemotherapeutic treatment. An important factor 
in the growth of residual tumor mass may be immune 
suppression in the early postoperative period and the 
production of pro-inflammatory cytokines. A mechanical 
effect on the tumor mass causes changes in the cell 
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Table 1.1. Group I (< 1 month interval)
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1 30 0 1 0.85868 1 33 13 1 0.4 0.232234 0.592497
2 30 0 1 0.85868 1 34 12 0 0.4 0.232234 0.592497
3 30 0 1 0.85868 1 35 12 1 0.366667 0.205428 0.560919
4 30 0 1 0.85868 1 36 11 0 0.366667 0.205428 0.560919
5 30 0 1 0.85868 1 37 11 0 0.366667 0.205428 0.560919
6 30 0 1 0.85868 1 38 11 0 0.366667 0.205428 0.560919
7 30 0 1 0.85868 1 39 11 1 0.333333 0.179376 0.528626
8 30 0 1 0.85868 1 40 10 0 0.333333 0.179376 0.528626
9 30 0 1 0.85868 1 41 10 0 0.333333 0.179376 0.528626
10 30 2 0.933333 0.764928 0.988368 42 10 0 0.333333 0.179376 0.528626
11 28 0 0.933333 0.764928 0.988368 43 10 3 0.333333 0.179376 0.528626
12 28 1 0.9 0.723237 0.973812 44 10 0 0.233333 0.10635 0.427002
13 27 0 0.9 0.723237 0.973812 45 7 0 0.233333 0.10635 0.427002
14 27 1 0.866667 0.683577 0.956403 46 7 0 0.233333 0.10635 0.427002
15 26 2 0.8 0.608693 0.915952 47 7 0 0.233333 0.10635 0.427002
16 24 1 0.766667 0.572998 0.89365 48 7 0 0.233333 0.10635 0.427002
17 23 1 0.733333 0.538273 0.870245 49 7 0 0.233333 0.10635 0.427002
18 22 2 0.666667 0.471374 0.820624 50 7 0 0.233333 0.10635 0.427002
19 20 2 0.6 0.407503 0.767766 51 7 1 0.2 0.084048 0.391307
20 18 1 0.566667 0.376614 0.740245 52 6 0 0.2 0.084048 0.391307
21 17 1 0.533333 0.346399 0.712034 53 6 1 0.166667 0.063036 0.35451
22 16 1 0.5 0.31685 0.68315 54 5 0 0.166667 0.063036 0.35451
23 15 0 0.5 0.31685 0.68315 55 5 0 0.166667 0.063036 0.35451
24 15 0 0.5 0.31685 0.68315 56 5 1 0.133333 0.043597 0.316423
25 15 1 0.466667 0.287966 0.653601 57 4 0 0.133333 0.043597 0.316423
26 14 1 0.433333 0.259755 0.623386 58 4 0 0.133333 0.043597 0.316423
27 13 0 0.433333 0.259755 0.623386 59 4 0 0.133333 0.043597 0.316423
28 13 0 0.433333 0.259755 0.623386 60 4 0 0.133333 0.043597 0.316423
29 13 0 0.433333 0.259755 0.623386 61 4 0 0.133333 0.043597 0.316423
30 13 0 0.433333 0.259755 0.623386 62 4 0 0.133333 0.043597 0.316423
31 13 0 0.433333 0.259755 0.623386 63 4 1 0.1 0.026188 0.276763
32 13 0 0.433333 0.259755 0.623386 64 3 0 0.1 0.026188 0.276763
structure, in the microenvironment of tumor cells, as well 
as changes in their participation in the cell division cycle 
and the metastatic process. An increase in the amount 
of mitotically active cells makes them more sensitive 
to chemotherapeutic drugs that affect the cell division 
cycle (for example, taxanes). Another factor affecting 
the increase in the growth rate of residual tumor cells is 
an increase in the production of angiogenesis factors.
In a study by Tewari K.S. et al. from the materials 
of phase III of a randomized, double-blind, place-
bo-controlled trial, the Gynecological Oncology Group 
protocol 218 obtained similar data on the increase in 
OS of patients with advanced ovarian cancer with ACT 
initiation up to 25 days from PDS [9]. Timmermans M. et 
al. proved that delayed ACT initiation is an independent 
predictor of OS reduction after cytoreductive surgery, 
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Table 1.2. Group I (< 1 month interval)
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65 3 0 0.1 0.026188 0.276763 96 2 0 0.066667 0.011632 0.235072
66 3 0 0.1 0.026188 0.276763 97 2 0 0.066667 0.011632 0.235072
67 3 0 0.1 0.026188 0.276763 98 2 0 0.066667 0.011632 0.235072
68 3 0 0.1 0.026188 0.276763 99 2 0 0.066667 0.011632 0.235072
69 3 0 0.1 0.026188 0.276763 100 2 0 0.066667 0.011632 0.235072
70 3 0 0.1 0.026188 0.276763 101 2 1 0.033333 0.001742 0.19053
71 3 0 0.1 0.026188 0.276763 102 1 0 0.033333 0.001742 0.19053
72 3 0 0.1 0.026188 0.276763 103 1 0 0.033333 0.001742 0.19053
73 3 0 0.1 0.026188 0.276763 104 1 0 0.033333 0.001742 0.19053
74 3 0 0.1 0.026188 0.276763 105 1 0 0.033333 0.001742 0.19053
75 3 0 0.1 0.026188 0.276763 106 1 0 0.033333 0.001742 0.19053
76 3 0 0.1 0.026188 0.276763 107 1 0 0.033333 0.001742 0.19053
77 3 0 0.1 0.026188 0.276763 108 1 0 0.033333 0.001742 0.19053
78 3 0 0.1 0.026188 0.276763 109 1 0 0.033333 0.001742 0.19053
79 3 0 0.1 0.026188 0.276763 110 1 0 0.033333 0.001742 0.19053
80 3 0 0.1 0.026188 0.276763 111 1 0 0.033333 0.001742 0.19053
81 3 0 0.1 0.026188 0.276763 112 1 0 0.033333 0.001742 0.19053
82 3 0 0.1 0.026188 0.276763 113 1 0 0.033333 0.001742 0.19053
83 3 0 0.1 0.026188 0.276763 114 1 0 0.033333 0.001742 0.19053
84 3 0 0.1 0.026188 0.276763 115 1 0 0.033333 0.001742 0.19053
85 3 1 0.066667 0.011632 0.235072 116 1 0 0.033333 0.001742 0.19053
86 2 0 0.066667 0.011632 0.235072 117 1 0 0.033333 0.001742 0.19053
87 2 0 0.066667 0.011632 0.235072 118 1 0 0.033333 0.001742 0.19053
88 2 0 0.066667 0.011632 0.235072 119 1 0 0.033333 0.001742 0.19053
89 2 0 0.066667 0.011632 0.235072 120 1 0 0.033333 0.001742 0.19053
90 2 0 0.066667 0.011632 0.235072 121 1 0 0.033333 0.001742 0.19053
91 2 0 0.066667 0.011632 0.235072 122 1 0 0.033333 0.001742 0.19053
92 2 0 0.066667 0.011632 0.235072 123 1 0 0.033333 0.001742 0.19053
93 2 0 0.066667 0.011632 0.235072 124 1 0 0.033333 0.001742 0.19053
94 2 0 0.066667 0.011632 0.235072 125 1 0 0.033333 0.001742 0.19053
95 2 0 0.066667 0.011632 0.235072 126 1 1 0 0 0.14132
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Table 2. Group II (2–6 months interval)
Time
period (months)
At risk Died Survival
probability
estimate
0.95  
Confidence 
interval lower limit
0.95 Confidence 
interval upper 
limit
1 30 0 1 0.85868 1
2 30 0 1 0.85868 1
3 30 0 1 0.85868 1
4 30 0 1 0.85868 1
5 30 4 0.866667 0.683577 0.956403
6 26 2 0.8 0.608693 0.915952
7 24 0 0.8 0.608693 0.915952
8 24 0 0.8 0.608693 0.915952
9 24 0 0.8 0.608693 0.915952
10 24 0 0.8 0.608693 0.915952
11 24 0 0.8 0.608693 0.915952
12 24 4 0.666667 0.471374 0.820624
13 20 0 0.666667 0.471374 0.820624
14 20 2 0.6 0.407503 0.767766
15 18 0 0.6 0.407503 0.767766
16 18 0 0.6 0.407503 0.767766
17 18 0 0.6 0.407503 0.767766
18 18 2 0.533333 0.346399 0.712034
19 16 10 0.2 0.084048 0.391307
20 6 0 0.2 0.084048 0.391307
21 6 0 0.2 0.084048 0.391307
22 6 0 0.2 0.084048 0.391307
23 6 0 0.2 0.084048 0.391307
24 6 0 0.2 0.084048 0.391307
25 6 0 0.2 0.084048 0.391307
26 6 0 0.2 0.084048 0.391307
27 6 2 0.133333 0.043597 0.316423
28 4 0 0.133333 0.043597 0.316423
29 4 0 0.133333 0.043597 0.316423
30 4 0 0.133333 0.043597 0.316423
31 4 0 0.133333 0.043597 0.316423
32 4 0 0.133333 0.043597 0.316423
33 4 0 0.133333 0.043597 0.316423
34 4 0 0.133333 0.043597 0.316423
35 4 2 0.066667 0.011632 0.235072
36 2 0 0.066667 0.011632 0.235072
37 2 0 0.066667 0.011632 0.235072
38 2 0 0.066667 0.011632 0.235072
39 2 0 0.066667 0.011632 0.235072
40 2 2 0 0 0.14132
41 0 0 0 0 0
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Figure 1. The distribution graphs of the survival of patients I — blue graph (the time interval before the start of ACT to 
1 month) and II — red graph (the time interval before the start of ACT from 2 to 6 months) of the Kaplan-Mayer groups 
with the 0.95 confidence interval shown by dotted lines
and determined the optimal interval of 5–6 weeks [10]. 
Seagle B.L. et al. performed a retrospective cohort study 
in patients who underwent special treatment according 
to the National Comprehensive Cancer Network guide-
line for 1998-2011 and determined an improvement 
in survival after ACT initiation within 21–35 days from 
PDS [11]. In a study by Joseph N. et al., patients with 
advanced ovarian cancer in the age group of 65 years 
were considered. Such patients quite often need to 
reduce the doses of ACT, as well as to delay its initi-
ation. The postponement of ACT is determined by an 
independent factor associated with a decrease in OS 
[12]. Similar results were also obtained by Liu Y. et al. 
in a meta-analysis of 14 studies with 59.569 patients 
with ovarian cancer. A decrease in OS with a prolonged 
interval prior to initiation of ACT was found, especially 
among patients with advanced ovarian cancer [13]. Lee 
Y. Y. et al. also noted a negative effect on OS with an 
increase in the intervals between the stages of special 
treatment of advanced epithelial ovarian cancer [14].
A similar effect is also exerted by a decrease in time 
between ACT cycles, which was reviewed by Starbuck 
K.D. et al. In their results, even short delays in the
passage of all cycles lead to a progressive decrease
in OS [15].
According to Olawaiye A.B. et al. another factor is 
dose modification in ACT regimens with carboplatin 
and paclitaxel. Dose reduction and delayed admission 
increases the risk of disease progression and reduces 
the OS of patients with advanced ovarian cancer [16].
The results of the Garcia-Soto A.E. et al. study are 
contradictory. There was demonstrated the lack of ef-
fect of time before initiation of adjuvant intraperitoneal 
chemotherapy on relapse-free survival and OS [17].
Lee Y.J. et al. noted the effect on OS of the time 
interval from completion of neoadjuvant chemother-
apeutic treatment to initiation of ACT in patients with 
ovarian cancer [18].
In a study, Chen M. et al. demonstrated a decrease 
in relapse-free survival over a time interval from com-
pletion of neoadjuvant chemotherapeutic treatment to 
cytoreductive surgery for more than 4 weeks, and the 
absence of the effect of this interval on OS [19].
Jeong S.J et al. noted the absence of a decrease 
in OS with delayed ACT after secondary cytoreductive 
surgery due to the progression of ovarian cancer dis-
ease [20].
Important prognostic factors for delaying the initi-
ation of chemotherapeutic treatment in patients were 
postoperative complications, which were often caused 
by the most aggressive surgical approach to achieve 
CC-0. It resulted in long periods of stay in a surgical
hospital. The treatment opportunities of the oncology
center have a great influence on the possibilities of early 
initiation of ACT because they determine the period of
postoperative recovery of the patient and the increase in 
options for further special treatment of residual disease.
Study Limitations
This study was a single center, retrospective and 
nonrandomized. The histological subtypes of ovarian 
adenocarcinoma of each patient, the degree of differ-
entiation of the tumors, and the Ki67 proliferation index, 
which probably had a slight effect on the homogeneity 
of the patient samples, were not taken into account 
when the groups were formed.
Prospects for further research 
The study of the effect of the interval between neo-
adjuvant chemotherapeutic treatment and cytoreductive 
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surgery is also promising. Comparison of the effective-
ness of neoadjuvant chemotherapeutic treatment and 
further cytoreductive surgery with PDS and adjuvant 
chemotherapeutic treatment at different intervals be-
tween the stages of each of the combined treatment 
regimens, assessing the quality of life of patients with 
different options and different treatment intensities is 
also relevant.
Conclusions
The results demonstrate a statistically significant dif-
ference in the overall survival of patients with advanced 
ovarian adenocarcinoma (FIGO IIIC–IV) who underwent 
optimal PDS and ACT according to the standard regi-
men in a time interval of up to one month compared to 
the group of patients with a delay of the second stage 
of treatment by 2–6 months. Thus, delaying the onset of 
ACT is an independent predictor of the worse OS after 
performing PDS. The results of our study highlight the 
importance of minimizing delays before starting adju-
vant chemotherapy. According to the data obtained, 
patients should start ACT within 1 month after surgery, 
which is predictive in achieving CC-0 in PDS.
Conflict of interest: The authors declare that there 
is no conflict of interest regarding the publication of 
this article.
Abbreviations:
ACT — adjuvant chemotherapeutic treatment 
OS — overall survival 
PDS — primary cytoreductive surgery 
CC — completeness of cytoreduction
References
1. Martinez A, Ngo C, Leblanc E, et al. Surgical Complexity Impact 
on Survival After Complete Cytoreductive Surgery for Advanced
Ovarian Cancer. Ann Surg Oncol. 2016; 23(8): 2515–2521, doi:
10.1245/s10434-015-5069-z, indexed in Pubmed: 27008588.
2. Xu X, Deng F, Lv M, et al. The number of cycles of neoadjuvant che-
motherapy is associated with prognosis of stage IIIc-IV high-grade
serous ovarian cancer. Arch Gynecol Obstet. 2017; 295(2): 451–458, 
doi: 10.1007/s00404-016-4256-x, indexed in Pubmed: 27913927.
3. Xiao Y, Xie S, Zhang N, et al. Platinum-Based Neoadjuvant Chemo-
therapy versus Primary Surgery in Ovarian Carcinoma International
Federation of Gynecology and Obstetrics Stages IIIc and IV: A Sys-
tematic Review and Meta-Analysis. Gynecol Obstet Invest. 2018; 83(3): 
209–219, doi: 10.1159/000485618, indexed in Pubmed: 29402804.
4. Kobal B, Noventa M, Cvjeticanin B, et al. Primary debulking surgery ver-
sus primary neoadjuvant chemotherapy for high grade advanced stage
ovarian cancer: comparison of survivals. Radiol Oncol. 2018; 52(3): 
307–319, doi: 10.2478/raon-2018-0030, indexed in Pubmed: 30210049.
5. Somashekhar SP. Does debulking of enlarged positive lymph nodes
improve survival in different gynaecological cancers? Best Pract Res 
Clin Obstet Gynaecol. 2015; 29(6): 870–883, doi: 10.1016/j.bpo-
bgyn.2015.04.010, indexed in Pubmed: 26043964.
6. Sinukumar S, Rajan F, Mehta S, et al. A comparison of outcomes
following total and selective peritonectomy performed at the time of
interval cytoreductive surgery for advanced serous epithelial ovarian, 
fallopian tube and primary peritoneal cancer - A study by INDEP-
SO. Eur J Surg Oncol. 2019 [Epub ahead of print], doi: 10.1016/j.
ejso.2019.02.031, indexed in Pubmed: 30857879.
7. Zhang G, Zhu Y, Liu C, et al. The prognosis impact of hyperthermic in-
traperitoneal chemotherapy (HIPEC) plus cytoreductive surgery (CRS) in 
advanced ovarian cancer: the meta-analysis. J Ovarian Res. 2019; 12(1): 
33, doi: 10.1186/s13048-019-0509-1, indexed in Pubmed: 30995948.
8. Le Saux O, Decullier E, Freyer G, et al. Long-term survival in patients 
with epithelial ovarian cancer following cytoreductive surgery and hy-
perthermic intraperitoneal chemotherapy (HIPEC). Int J Hyperthermia.
2018; 35(1): 652–657, doi: 10.1080/02656736.2018.1518544, indexed 
in Pubmed: 30295114.
9. Tewari KS, Java JJ, Eskander RN, et al. Early initiation of chemotherapy 
following complete resection of advanced ovarian cancer associated 
with improved survival: NRG Oncology/Gynecologic Oncology Group 
study. Ann Oncol. 2016; 27(1): 114–121, doi: 10.1093/annonc/mdv500, 
indexed in Pubmed: 26487588.
10. Timmermans M, van der Aa MA, Lalisang RI, et al. Interval between 
debulking surgery and adjuvant chemotherapy is associated with
overall survival in patients with advanced ovarian cancer. Gynecol
Oncol. 2018; 150(3): 446–450, doi: 10.1016/j.ygyno.2018.07.004, 
indexed in Pubmed: 30001834.
11. Seagle BLL, Butler SK, Strohl AE, et al. Chemotherapy delay after 
primary debulking surgery for ovarian cancer. Gynecol Oncol. 2017;
144(2): 260–265, doi: 10.1016/j.ygyno.2016.11.022, indexed in
Pubmed: 27908531.
12. Joseph N, Clark RM, Dizon DS, et al. Delay in chemotherapy ad-
ministration impacts survival in elderly patients with epithelial ovar-
ian cancer. Gynecol Oncol. 2015; 137(3): 401–405, doi: 10.1016/j.
ygyno.2015.03.052, indexed in Pubmed: 25839911.
13. Liu Yi, Zhang T, Wu Q, et al. Relationship between initiation time of adju-
vant chemotherapy and survival in ovarian cancer patients: a dose-re-
sponse meta-analysis of cohort studies. Sci Rep. 2017; 7(1): 9461,
doi: 10.1038/s41598-017-10197-1, indexed in Pubmed: 28842667.
14. Lee YY, Lee JW, Lu L, et al. Impact of interval from primary cytoreductive 
surgery to initiation of adjuvant chemotherapy in advanced epithelial 
ovarian cancer. Int J Gynaecol Obstet. 2018; 143(3): 325–332, doi:
10.1002/ijgo.12653, indexed in Pubmed: 30129040.
15. Starbuck KD, Szender JB, Duncan WD, et al. Prognostic impact of 
adjuvant chemotherapy treatment intensity for ovarian cancer. PLoS 
One. 2018; 13(11): e0206913, doi: 10.1371/journal.pone.0206913, 
indexed in Pubmed: 30418985.
16. Olawaiye AB, Java JJ, Krivak TC, et al. Does adjuvant chemotherapy 
dose modification have an impact on the outcome of patients diag-
nosed with advanced stage ovarian cancer? An NRG Oncology/Gyne-
cologic Oncology Group study. Gynecol Oncol. 2018; 151(1): 18–23, 
doi: 10.1016/j.ygyno.2018.07.021, indexed in Pubmed: 30135020.
17. Garcia-Soto AE, Java JJ, Nieves Neira W, et al. Does time interval between
surgery and intraperitoneal chemotherapy administration in advanced
ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic 
Oncology Group study ancillary study. Gynecol Oncol. 2016; 143(3): 484–
489, doi: 10.1016/j.ygyno.2016.10.003, indexed in Pubmed: 27726923.
18. Lee YJ, Chung YS, Lee JY, et al. Impact of the time interval from com-
pletion of neoadjuvant chemotherapy to initiation of postoperative
adjuvant chemotherapy on the survival of patients with advanced
ovarian cancer. Gynecol Oncol. 2018; 148(1): 62–67, doi: 10.1016/j.
ygyno.2017.11.023, indexed in Pubmed: 29174056.
19. Chen M, Chen Z, Xu M, et al. Impact of the Time Interval from Neo-
adjuvant Chemotherapy to Surgery in Primary Ovarian, Tubal, and
Peritoneal Cancer Patients. J Cancer. 2018; 9(21): 4087–4091, doi:
10.7150/jca.26631, indexed in Pubmed: 30410613.
20. Jeong SY, Choi CH, Kim TJ, et al. Interval between secondary cytoreduc-
tive surgery and adjuvant chemotherapy is not associated with survivals
in patients with recurrent ovarian cancer. J Ovarian Res. 2019; 13(1):
1, doi: 10.1186/s13048-019-0602-5, indexed in Pubmed: 31892329.
